recent pharma news

View All

pharma-news
CanSino deals with Precision; Atea raises USD 215 M; Applied Molecular Transport targets for USD 100 M IPO; Cell therapy repairs multiple sclerosis in mice

CanSino adds mRNA with Precision NanoSystems  CanSino Biologics is already evaluating a recombinant coronavirus vaccine in China. However, it is adding the mRNA to COVID-19 vaccine through a licensing agreement with Precision NanoSystems. The partners will work on an mRNA nanoparticle vaccine for COVID-1...

Find More

pharma-news
Mavacamten Phase III clinical trial, FDA nod for Ovarian cancer therapy, Dyno Therapeutics & Novartis Collaboration, Abbott’s COVID-19 diagnostic kit

MyoKardia has announced the promising results of Phase III clinical trials of its lead drug mavacamten for symptomatic, obstructive hypertrophic cardiomyopathy (HCM). Following the announcement, shares of the California-based company skyrocketed. The Phase III clinical trial - EXPLORER-HCM – demonstrated the pot...

Find More

pharma-news
Acquisition of Stemline; Roche’s Elecsys Anti-SARS-CoV-2 antibody test; Newron’s abandonment of STARS trial

Florence-based Menarini Group has announced a USD667 million acquisition of the Stemline Therapeutics, an oncology-focused company. As per the agreement, Menarini plans to help Stemline to build a strong foothold in the U.S., and will also continue the development of Elzonris, a CD123 targeted therapy. Th...

Find More

Latest COVID-19/ SARS-CoV-2 news
In the race to fight SARS-CoV-2: Merck, ISB; ViiV; Genalyte gears up

Merck has collaborated with the Seattle-based Institute for Systems Biology (ISB) to further study novel coronavirus SARS-CoV-2. The primary goal of the collaboration will be to investigate the molecular pathway of SARS-CoV-2 and aetiology of COVID-19 with the intent of finding an effective and standard treatm...

Find More

COVID-19-pipeline-development
COVID19 pipeline advances as Novartis begins phase III trial of hydroxychloroquine; and advancements in RCC, and HER2 positive breast cancer market

The U.S. FDA has given its nod to Seattle Genetics for its Tukysa (tucatinib) for advanced unresectable or metastatic HER2-positive breast cancer Genetics Tukysa (tucatinib) is a tyrosine kinase inhibitor of the HER2 protein, administered orally in combination with chemotherapy agents trastuzumab and capec...

Find More

pharma news
Vir’s drug shows results; Abbott launches coronavirus antibody lab test; Reprogrammed skin cells repair vision in mouse models; Moma Therapeutics focuses for molecular machines

Vir's Hepatitis B drug shows positive results in phase 2 The hepatitis B drug of Vir Biotechnology has shown promising results. Its gene-silencing drug trim levels of the hepatitis B surface antigen in a small phase 2 study in patients who are already taking antiretroviral drugs. The drug, VIR-2218,...

Find More

covid-news
In the fight against COVID-19 – Lilly with Olumiant, Gilead with remdesivir, Rutgers with testing kit

Eli Lilly has announced to begin clinical trials of rheumatoid arthritis drug Olumiant to treat COVID-19 patients.  The company plans to explore the anti-inflammatory responses that were witnessed in rheumatoid arthritis patients, and how the drug – Olumiant – an oral JAK1/JAK2 inhibitor – might help in cur...

Find More

pharma news
AstraZeneca targets for COVID-19 antibody trial; Arrakis, Roche team up; GSK, AstraZeneca launch testing lab, U.S. government funds OraSure

AstraZeneca aims for summer start for COVID-19 antibody trial AstraZeneca has made its multipronged approach to the development of antibodies against the pandemic SARS-CoV-2 virus. The giant is utilizing its discovery capabilities and assisting in assessing the candidates who were identified in China and the U.S...

Find More

pharma news
Immunomedics Halts Sacituzumab govitecan trial; GSK-Vir Biotech collaboration; INO-4800 DNA COVID-19 Vaccine; Pfizer Commits $ 40M for COVID-19

Immunomedics discontinues its trial early – hopes for accelerated approval of Sacituzumab govitecan for mTNBC Immunomedics- a New Jersey-based pharmaceutical company has announced to freeze its Phase III confirmatory ASCENT clinical trial of sacituzumab govitecan aimed at treating metastatic triple-negative brea...

Find More

COVID-19 Pharma News
J&J’s COVID-19 Vaccine; GigaGen COVID-19 therapy; FDA approved Abbott’s POC test; Cobra Bio raises $ 3.3 M

Johnson & Johnson is fast-forwarding its vaccine development program for COVID-19.  The healthcare company has selected a lead vaccine candidate and is planning to begin human trials in September, with first batches available under potential emergency use authorization in the first part of 2021. The ...

Find More